Silymarin

Exact transparent composition and a current peer-reviewed exact-product pilot improve traceability, but complementary-feed oversight, open-label design and manufacturer conflicts leave credibility moderate.

The 17-dog open-label pilot found improved liver biomarkers after eight weeks, but no control, small heterogeneous sample, sponsor involvement and no patient-centred or durable outcomes prevent a causal efficacy claim.

Seventeen dogs completed eight weeks without reported adverse effects, supporting short-term tolerability only; no controlled frequency estimate, long-term, reproductive or severe-disease safety is available.

Oral administration is manageable, but the every-other-day to daily transition at 10 kg and mismatch between the current low-weight label and the pilot regimen require careful schedule selection.

Exact composition and category are transparent, but the only exact-product peer-reviewed trial is canine, open-label and manufacturer-linked; no feline dossier or trial supports the assessed species.

Advanced has a small positive dog pilot but no feline outcome study; canine biomarkers and ingredient mechanisms do not validate the current feline schedule or clinical benefit.

No exact feline target-animal safety study or adverse-event frequency is available. Manufacturer silence cannot prove safety; soy, GI tolerance, concurrent supplements and product-specific ingredients require review.

A whole tablet every other day avoids fractional dosing for cats up to 10 kg, but no schedule exists above that boundary and the canine daily pilot does not validate feline administration.

Exact current identity and complementary-feed category are clear, but the manufacturer omits ingredient quantities and detailed cat instructions; those rely on a retailer reproduction, quality standardisation is incomplete and no exact-product trial exists.

Ingredient mechanisms and limited dog studies are plausible, but consensus and reviews find weak clinical-outcome evidence; no Hepatosil trial exists, and recent SAMe+silymarin data showed minimal effect without disease-specific therapy.

The ingredients are commonly used adjuncts and serious toxicity is not prominent in indirect sources, but exact-product adverse-event rates, long-term diseased-dog safety, interaction testing and reproductive data are absent.

Once-daily oral use is manageable, but fasting/food separation, double-coat versus crushing uncertainty, ambiguous dosing above 10 kg and undefined duration add meaningful burden.

Exact current identity and complementary-feed category are clear, but the manufacturer omits ingredient quantities and detailed cat instructions; those rely on a retailer reproduction, quality standardisation is incomplete and no exact-product trial exists.

Feline evidence consists mainly of small experimental SAMe studies using different enteric-coated products; it does not establish benefit for spontaneous feline liver disease or this five-ingredient tablet.

A small healthy-cat study supports tolerability of a different SAMe product, but exact-formulation safety in ill cats, interactions, long-term use and reproductive groups are unestablished.

Once-daily use is simple, but the unscored half-tablet dose is not accuracy-validated, fasting and coating/crushing uncertainty remain, and a separate MINI presentation is better matched to small animals.

Exact 140 mg/30-capsule identity, World Medicine information and active Georgian and Azerbaijani human registrations are traceable, but EU/GB/US status remains unknown. It is not veterinary-authorised, and all efficacy evidence is indirect or formulation-mismatched, so the PLAYBOOK evidence gate caps scientific credibility at 4.0.

Canine consensus and reviews support antioxidant/anti-inflammatory plausibility but call clinical benefit equivocal. Small studies use different silybin products, complexes or mixed formulations and mostly report biomarkers, not histology, survival or durable disease control. No exact Silarsil outcome trial was found.

The human label and indirect canine studies suggest generally manageable GI and hypersensitivity risk, but exact dog adverse-event frequency, chronic organ-disease exposure, extract variability and interaction magnitude are unknown. Silymarin can inhibit CYP450/P-glycoprotein; polypharmacy requires review.

Whole-capsule oral administration is simple only for dogs whose independently justified amount is close to 140 mg. Native-extract dose remains poorly defined, repeated administration may be required, and the capsule cannot be assumed openable or equally divisible.

Exact 140 mg/30-capsule identity, World Medicine information and active Georgian and Azerbaijani human registrations are traceable, but EU/GB/US status remains unknown. It is not veterinary-authorised, and all efficacy evidence is indirect or formulation-mismatched, so the PLAYBOOK evidence gate caps scientific credibility at 4.0.

No exact Silarsil or native-silymarin clinical outcome trial in cats was found. The feline evidence base is sparse and dominated by mechanisms, reviews or other products; canine and human findings cannot establish benefit in naturally occurring feline hepatobiliary disease.

Exact feline target-animal safety is absent. Human label tolerance and other-species studies are indirect; the capsule contains lactose, colourants and bovine gelatin, and milk-thistle/Asteraceae hypersensitivity, GI effects and CYP/P-glycoprotein interactions remain relevant uncertainties.

One 140 mg whole capsule is grossly mismatched to a typical cat relative to the uncertain native-extract range. The label requires swallowing whole, and opening, equal powder subdivision, food mixing, palatability and partial-capsule stability are unvalidated.